Ten Years of Incidental, Secondary, and Actionable Findings

In 2013, as sequencing tests that evaluated the genome or its coding regions (the exome) became available to aid in the diagnosis of suspected genetic disorders, the American College of Medical Genetics and Genomics (ACMG) issued a guideline(1) that included a set of medically important genes to be evaluated and reported independently of the indication for the test. Originally referred to as the ACMG Incidental Findings, this reporting guideline has undergone multiple updates and is now known as ACMG Secondary Findings (SF).(2) ACMG SF, version 3.0 (ACMG SF v3.0), recommends the reporting of pathogenic or likely pathogenic variants in 83 . . .